Modus presented at SCD Therapeutics Conference in New York 2016
Modus’ former CEO Christina Herder presented at the 5th Annual Sickle Cell Disease Therapeutics Conference 2016 in New York.
In her presentation, Dr Herder outlined Modus’s development plans for sevuparin, a novel drug the Company believes could offer a significant improvement of treatments in SCD. Sevuparin has the potential to normalize the lives of SCD patients, either by:
- Shortening hospital stays which result from an acute vaso-occlusive crisis (VOC); or
- Abolishing the need for hospitalization via patients being able to self-administer the drug when they believe a VOC is imminent
Modus Therapeutics is currently enrolling SCD patients into a multi-centre, international, randomized Phase II study in Europe and the Middle East. More details about the study can be found here.
The Annual Sickle-Cell Disease Therapeutics Conference is a forum to discuss the latest advancements and future trends for treating patients with sickle-cell disease. The annual event also features presentations from clinical-stage companies, key opinion leaders, patients and healthcare analysts. Find out more about the conference.